A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Authors
Keywords
-
Journal
Infectious Diseases and Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-05-27
DOI
10.1007/s40121-022-00644-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A neutrophil activation signature predicts critical illness and mortality in COVID-19
- (2021) Matthew L. Meizlish et al. Blood Advances
- The prognostic value of IL-8 for the death of severe or critical patients with COVID-19
- (2021) Hui Li et al. MEDICINE
- Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort in Wuhan, China
- (2021) Li Liu et al. Engineering
- A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
- (2021) Lori J. Goldstein et al. BREAST CANCER RESEARCH AND TREATMENT
- COVID‐19 and islet transplantation: different twins
- (2020) Lorenzo Piemonti et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage
- (2020) Jingyuan Liu et al. Journal of Translational Medicine
- The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities
- (2020) Louis Maximilian Buja et al. CARDIOVASCULAR PATHOLOGY
- A meta‐analysis of SARS‐CoV‐2 patients identifies the combinatorial significance of D‐dimer, C‐reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity
- (2020) Kunwar Singh et al. International Journal of Laboratory Hematology
- SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology
- (2020) Flavio Protasio Veras et al. JOURNAL OF EXPERIMENTAL MEDICINE
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Neutrophils and COVID-19: The road so far
- (2020) Luiz Henrique Agra Cavalcante-Silva et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Particulate Matter Increases the Severity of Bleomycin-Induced Pulmonary Fibrosis through KC-Mediated Neutrophil Chemotaxis
- (2019) I-Yin Cheng et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor
- (2018) Koa Hosoki et al. CLINICAL AND EXPERIMENTAL ALLERGY
- NET balancing: a problem in inflammatory lung diseases
- (2013) Olivia Z. Cheng et al. Frontiers in Immunology
- Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice
- (2008) A Zarbock et al. BRITISH JOURNAL OF PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now